ClinicalTrials.gg
CompletedNCT04659863ORION-13Updated Jan 13, 2026Results posted

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

A Phase 3 interventional study of Inclisiran and Placebo in Familial Hypercholesterolemia - Homozygous, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in 8 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Homozygous Familial Hypercholesterolemia with a site in Greece — 2 open to participants now, 3 under way, 2 of them phase 3. Homozygous Familial Hypercholesterolemia · Greece.

Started
2021
the only one that year
Phase 3
7 of 10
2 open now
Registered
7th of 10
by date
Lead sponsor
3 of 10
Novartis Pharmaceuticals

Among the 10 studies in Homozygous Familial Hypercholesterolemia with a site in Greece, this one is the only one that started in 2021, is one of 7 in phase 3, and was the 7th registered.

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

Browse Homozygous Familial Hypercholesterolemia studies →

Open to participants now

2 of the 10 studies in Homozygous Familial Hypercholesterolemia with a site in Greece are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Homozygous Familial Hypercholesterolemia with a site in Greece, or all of them as a file.
02

Study summary

This was a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C).

Read the detailed description

This was a two-part (double-blind, inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) multicenter study in adolescents (aged 12 to \< 18 years) with HoFH and elevated LDL-C (> 130 mg/dL; 3.4 mmol/L) on stable, individualized, optimal standard of care (SoC) background lipid-lowering therapy (including maximally tolerated statin treatment, at the Investigator's discretion) to evaluate the safety, tolerability, and efficacy of inclisiran in this pediatric patient population.

Following an approximately 4-week screening/run-in period, the study had 2 sequential parts as follows:

Part 1/Year 1: 12 months double-blind, parallel group period, in which participants were randomized in a 2:1 ratio to receive either inclisiran sodium 300 mg subcutaneous (s.c.) or placebo. The primary endpoint was assessed at Day 330.

Part 2/Year 2: 12 months single arm, open-label follow-up period, with all participants receiving inclisiran sodium 300 mg s.c.

03

Conditions studied

  • Familial Hypercholesterolemia - Homozygous

Keywords

  • Homozygous familial hypercholesterolemia (HoFH)
  • LDL-cholesterol (LDL-C)
  • adolescents
  • pediatric
  • small interfering ribonucleic acid (siRNA)
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Homozygous Familial Hypercholesterolemia (HoFH) diagnosed by genetic confirmation
  • Fasting LDL-C >130 mg/dL (3.4 mmol/L) at screening
  • On maximally tolerated dose of statin (investigator's discretion) with or without other lipid-lowering therapy; stable for ≥ 30 days before screening
  • Male or female participants >=12 to \<18 years of age at screening

Exclusion criteria

Exclusion Criteria:

  • Documented evidence of a null (negative) mutation in both LDLR alleles
  • Heterozygous familial hypercholesterolemia (HeFH)
  • Active liver disease
  • Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome
  • Previous treatment with monoclonal antibodies directed towards PCSK9 (within 90 days of screening)
  • Treatment with mipomersen or lomitapide (within 5 months of screening)
  • Recent and/or planned use of other medicinal products or devices
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Part 1 - Inclisiran

    Inclisiran sodium 300 mg subcutaneous (sc) injection (given at Days 1, 90 and 270)

    Drug: Inclisiran

  • Placebo comparator
    Part 1 - Placebo

    Placebo sc injection (given at Day 1, 90 and 270)

    Drug: Placebo

  • Experimental
    Part 2 - Inclisiran (Total)

    Inclisiran sodium 300 mg sc injection (given at Days 450 and 630). In addition, participants assigned to placebo in Part 1 received inclisiran sodium 300 mg sc injection on Day 360, while participants assigned to inclisiran in Part 1 received placebo sc injection on Day 360.

    Drug: Inclisiran

Interventions

  • Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection

    Also known as: KJX839

  • DrugPlacebo

    Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection

    Also known as: Saline solution

06

What researchers measure

Primary outcomes

  1. Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)

    Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 (Year 1)

    Time frame: Baseline and Day 330

Secondary outcomes

  1. Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1)

    Time-adjusted percent change in LDL-C (after Day 90 and up to Day 330), calculated as the average of percent changes from baseline to Days 150, 270 and 330

    Time frame: Baseline, after Day 90 up to Day 330

  2. Percent Change in LDL-C From Baseline up to Day 720

    Percentage change in LDL-C from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  3. Absolute Change in LDL-C From Baseline up to Day 720

    Absolute change in LDL-C from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  4. Percent Change in Apo B From Baseline up to Day 720

    Percentage change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  5. Absolute Change in Apo B From Baseline up to Day 720

    Absolute change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  6. Percent Change in Lp(a) From Baseline up to Day 720

    Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  7. Absolute Change in Lp(a) From Baseline up to Day 720

    Absolute change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  8. Percent Change in Non-HDL-C From Baseline up to Day 720

    Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  9. Absolute Change in Non-HDL-C From Baseline up to Day 720

    Absolute change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  10. Percent Change in Total Cholesterol From Baseline up to Day 720

    Percentage change in total cholesterol from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  11. Absolute Change in Total Cholesterol From Baseline up to Day 720

    Absolute change in total cholesterol from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  12. Percent Change in Triglycerides From Baseline up to Day 720

    Percentage change in triglycerides from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  13. Absolute Change in Triglycerides From Baseline up to Day 720

    Absolute change in triglycerides from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  14. Percent Change in HDL-C From Baseline up to Day 720

    Percentage change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  15. Absolute Change in HDL-C From Baseline up to Day 720

    Absolute change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  16. Percent Change in VLDL-C From Baseline up to Day 720

    Percentage change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  17. Absolut Change in VLDL-C From Baseline up to Day 720

    Absolute change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  18. Percent Change in Apo A1 From Baseline up to Day 720

    Percentage change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  19. Absolute Change in Apo A1 From Baseline up to Day 720

    Absolute change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  20. Percent Change in PCSK9 From Baseline up to Day 720

    Percentage change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

  21. Absolut Change in PCSK9 From Baseline up to Day 720

    Absolute change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.

    Time frame: Baseline, up to Day 720

07

Results

Posted May 31, 2025

Participant flow

Thirteen participants were randomized from 9 study centers in 8 countries. The breakdown of countries and study centers for the randomized participants was as follows: Canada (1), France (1), Greece (1), Lebanon (1), Malaysia (1), Netherlands (1), Turkey (2), and United States (1).

Part 1 (Double-blind Period)
Participant flow — Part 1 (Double-blind Period)
MilestonePart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Started940
Completed940
Not completed000
Part 2 (Open-label Period)
Participant flow — Part 2 (Open-label Period)
MilestonePart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Started0013
Completed0013
Not completed000

Outcome measures

PrimaryPercentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)

Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 (Year 1)

Time frame:
Baseline and Day 330
Reported as:
Mean · percent change in LDL-C
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)
percent change in LDL-CPart 1- InclisiranPart 1 - Placebo
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)-21.6 ± 13.3611.7 ± 30.52
Statistical analysis
  • Part 1- Inclisiran vs Part 1 - Placebo · Mean difference (net): -33.25 · 95% CI -59.17 to -7.34
SecondaryTime-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1)

Time-adjusted percent change in LDL-C (after Day 90 and up to Day 330), calculated as the average of percent changes from baseline to Days 150, 270 and 330

Time frame:
Baseline, after Day 90 up to Day 330
Reported as:
Mean · Time-adjusted percent change in LDL-C
Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1)
Time-adjusted percent change in LDL-CPart 1- InclisiranPart 1 - Placebo
Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1)-21.0 ± 15.1113.0 ± 41.88
SecondaryPercent Change in LDL-C From Baseline up to Day 720

Percentage change in LDL-C from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in LDL-C
Percent Change in LDL-C From Baseline up to Day 720
Percent change in LDL-CPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 90-26.1 ± 13.536.8 ± 16.83—
Day 150-24.1 ± 14.6517.0 ± 41.22—
Day 270-17.3 ± 21.6410.2 ± 54.00—
Day 330-21.6 ± 13.3611.7 ± 30.52—
Day 360-19.3 ± 14.755.4 ± 28.24—
Day 450——-11.0 ± 25.28
Day 510——-12.5 ± 22.52
Day 630——-9.4 ± 26.16
Day 720——-12.6 ± 28.45
SecondaryAbsolute Change in LDL-C From Baseline up to Day 720

Absolute change in LDL-C from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in LDL-C From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 90-70.6 ± 48.8116.5 ± 44.96—
Day 150-66.1 ± 61.8520.3 ± 91.34—
Day 270-47.1 ± 83.15-9.3 ± 134.14—
Day 330-62.9 ± 52.3511.8 ± 69.94—
Day 360-50.8 ± 44.65-4.3 ± 69.84—
Day 450——-36.6 ± 75.08
Day 510——-46.8 ± 73.04
Day 630——-41.9 ± 92.47
Day 720——-39.8 ± 96.59
SecondaryPercent Change in Apo B From Baseline up to Day 720

Percentage change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in Apo B
Percent Change in Apo B From Baseline up to Day 720
Percent change in Apo BPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-20.3 ± 12.9210.0 ± 27.05—
Day 330-18.5 ± 10.474.5 ± 17.91—
Day 360-14.8 ± 10.1110.6 ± 21.33—
Day 510——-5.7 ± 25.96
Day 720 (study completion)——-7.3 ± 29.36
SecondaryAbsolute Change in Apo B From Baseline up to Day 720

Absolute change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in Apo B From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-37.3 ± 33.357.5 ± 48.72—
Day 330-35.8 ± 30.330.3 ± 35.85—
Day 360-28.7 ± 27.1612.0 ± 32.89—
Day 510——-18.8 ± 45.81
Day 720 (study completion)——-19.6 ± 51.64
SecondaryPercent Change in Lp(a) From Baseline up to Day 720

Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in Lp(a)
Percent Change in Lp(a) From Baseline up to Day 720
Percent change in Lp(a)Part 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-0.7 ± 24.81-4.4 ± 9.20—
Day 330-0.3 ± 21.27-16.5 ± 27.29—
Day 360-1.7 ± 16.57-12.1 ± 31.51—
Day 510——-7.2 ± 31.39
Day 720 (study completion)——-8.8 ± 22.03
SecondaryAbsolute Change in Lp(a) From Baseline up to Day 720

Absolute change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · nmol/L
Absolute Change in Lp(a) From Baseline up to Day 720
nmol/LPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 1508.9 ± 28.41-0.3 ± 1.26—
Day 3302.8 ± 15.015.3 ± 15.86—
Day 3605.8 ± 7.030.5 ± 9.75—
Day 510——3.0 ± 14.45
Day 720 (study completion)——-0.3 ± 9.12
SecondaryPercent Change in Non-HDL-C From Baseline up to Day 720

Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in non-HDL-C
Percent Change in Non-HDL-C From Baseline up to Day 720
Percent change in non-HDL-CPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-24.0 ± 13.8319.0 ± 43.34—
Day 330-23.3 ± 10.999.4 ± 34.93—
Day 360-20.1 ± 10.917.1 ± 24.38—
Day 510——-11.8 ± 25.33
Day 720 (study completion)——-13.0 ± 23.65
SecondaryAbsolute Change in Non-HDL-C From Baseline up to Day 720

Absolute change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in Non-HDL-C From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-73.8 ± 68.0128.8 ± 94.01—
Day 330-74.4 ± 57.634.3 ± 82.16—
Day 360-60.0 ± 44.746.0 ± 56.11—
Day 510——-51.4 ± 81.53
Day 720 (study completion)——-45.8 ± 89.10
SecondaryPercent Change in Total Cholesterol From Baseline up to Day 720

Percentage change in total cholesterol from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in total cholesterol
Percent Change in Total Cholesterol From Baseline up to Day 720
Percent change in total cholesterolPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-19.0 ± 12.4916.0 ± 37.96—
Day 330-19.1 ± 10.308.7 ± 30.54—
Day 360-16.1 ± 9.536.8 ± 21.06—
Day 510——-9.3 ± 20.73
Day 720 (study completion)——-9.6 ± 20.86
SecondaryAbsolute Change in Total Cholesterol From Baseline up to Day 720

Absolute change in total cholesterol from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in Total Cholesterol From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-69.7 ± 67.4229.5 ± 99.30—
Day 330-71.4 ± 56.658.8 ± 84.68—
Day 360-57.3 ± 43.8210.0 ± 59.14—
Day 510——-46.5 ± 80.87
Day 720 (study completion)——-40.4 ± 88.44
SecondaryPercent Change in Triglycerides From Baseline up to Day 720

Percentage change in triglycerides from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in triglycerides
Percent Change in Triglycerides From Baseline up to Day 720
Percent change in triglyceridesPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 1500.3 ± 31.92-15.7 ± 5.97—
Day 330-9.6 ± 30.66-5.8 ± 31.90—
Day 36011.4 ± 24.7214.1 ± 54.93—
Day 510——4.7 ± 37.21
Day 720 (study completion)——2.9 ± 26.02
SecondaryAbsolute Change in Triglycerides From Baseline up to Day 720

Absolute change in triglycerides from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in Triglycerides From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-3.4 ± 23.80-15.0 ± 7.53—
Day 330-9.4 ± 21.98-2.3 ± 25.01—
Day 3608.7 ± 24.1528.0 ± 72.23—
Day 510——3.3 ± 34.32
Day 720 (study completion)——3.9 ± 27.40
SecondaryPercent Change in HDL-C From Baseline up to Day 720

Percentage change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in HDL-C
Percent Change in HDL-C From Baseline up to Day 720
Percent change in HDL-CPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 15010.0 ± 13.22-0.1 ± 20.06—
Day 3307.5 ± 12.9310.9 ± 12.48—
Day 3606.7 ± 20.609.2 ± 21.20—
Day 510——12.3 ± 17.63
Day 720 (study completion)——13.9 ± 18.81
SecondaryAbsolute Change in HDL-C From Baseline up to Day 720

Absolute change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in HDL-C From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 1504.1 ± 5.180.8 ± 7.50—
Day 3303.0 ± 5.054.5 ± 5.07—
Day 3602.7 ± 7.754.0 ± 8.76—
Day 510——4.9 ± 7.94
Day 720 (study completion)——5.4 ± 7.81
SecondaryPercent Change in VLDL-C From Baseline up to Day 720

Percentage change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in VLDL-C
Percent Change in VLDL-C From Baseline up to Day 720
Percent change in VLDL-CPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-7.0 ± 70.3174.5 ± 108.97—
Day 330-29.0 ± 49.962.0 ± 113.44—
Day 360-17.0 ± 60.3634.6 ± 56.37—
Day 510——9.5 ± 98.44
Day 720 (study completion)——-1.4 ± 69.03
SecondaryAbsolut Change in VLDL-C From Baseline up to Day 720

Absolute change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolut Change in VLDL-C From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-7.7 ± 11.398.5 ± 20.37—
Day 330-11.6 ± 11.71-7.5 ± 18.21—
Day 360-9.2 ± 17.8910.3 ± 21.00—
Day 510——-4.6 ± 18.41
Day 720 (study completion)——-6.0 ± 18.81
SecondaryPercent Change in Apo A1 From Baseline up to Day 720

Percentage change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in Apo A1
Percent Change in Apo A1 From Baseline up to Day 720
Percent change in Apo A1Part 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-0.9 ± 10.72-1.3 ± 2.27—
Day 330-2.1 ± 10.879.0 ± 7.02—
Day 3603.1 ± 16.4913.7 ± 12.99—
Day 510——12.8 ± 12.08
Day 720 (study completion)——6.5 ± 10.10
SecondaryAbsolute Change in Apo A1 From Baseline up to Day 720

Absolute change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · mg/dL
Absolute Change in Apo A1 From Baseline up to Day 720
mg/dLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 150-1.2 ± 14.10-1.3 ± 2.36—
Day 330-2.7 ± 13.4710.3 ± 7.41—
Day 3604.2 ± 18.8216.0 ± 14.79—
Day 510——14.9 ± 13.25
Day 720 (study completion)——7.4 ± 12.40
SecondaryPercent Change in PCSK9 From Baseline up to Day 720

Percentage change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · Percent change in PCSK9
Percent Change in PCSK9 From Baseline up to Day 720
Percent change in PCSK9Part 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 90-56.8 ± 13.73-17.3 ± 14.77—
Day 150-60.4 ± 12.62-1.7 ± 11.11—
Day 330-65.3 ± 12.51-5.1 ± 19.60—
Day 360-59.7 ± 9.05-2.8 ± 22.65—
Day 510——-68.1 ± 10.57
Day 720 (study completion)——-64.1 ± 12.12
SecondaryAbsolut Change in PCSK9 From Baseline up to Day 720

Absolute change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to each assessment time up to Day 720.

Time frame:
Baseline, up to Day 720
Reported as:
Mean · ng/mL
Absolut Change in PCSK9 From Baseline up to Day 720
ng/mLPart 1- InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
Day 90-278.7 ± 113.31-98.5 ± 87.46—
Day 150-296.3 ± 118.18-6.1 ± 64.82—
Day 330-323.1 ± 129.32-35.3 ± 100.97—
Day 360-292.6 ± 100.44-14.0 ± 127.42—
Day 510——-347.3 ± 106.3
Day 720 (study completion)——-327.7 ± 110.4

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 90 days post treatment or 30 days after last study visit, whichever was longer, up to a maximum duration of approximately 2 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 - Inclisiran0/9 (0%)0/9 (0%)7/9 (77.8%)
Part 1 - Placebo0/4 (0%)0/4 (0%)1/4 (25%)
Part 2 - Inclisiran (Total)0/13 (0%)0/13 (0%)8/13 (61.5%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPart 1 - InclisiranPart 1 - PlaceboPart 2 - Inclisiran (Total)
COVID-19Infections and infestations4/91/41/13
GastroenteritisInfections and infestations1/91/40/13
GingivitisInfections and infestations0/91/40/13
Oral herpesInfections and infestations0/91/40/13
Vaginal dischargeReproductive system and breast disorders0/91/40/13
AngioedemaSkin and subcutaneous tissue disorders0/91/40/13
UrticariaSkin and subcutaneous tissue disorders0/91/40/13
Abdominal pain upperGastrointestinal disorders2/90/41/13
Injection site reactionGeneral disorders2/90/40/13
PyrexiaGeneral disorders2/90/40/13

Baseline characteristics

Baseline Characteristics are based on all randomized participants

Age, Categorical
Age, Categorical(Participants)Part 1- InclisiranPart 1 - PlaceboTotal
<=18 years9413
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)Part 1- InclisiranPart 1 - PlaceboTotal
Mean14.6 ± 1.5415.1 ± 2.6614.8 ± 1.85
Sex: Female, Male
Sex: Female, Male(Participants)Part 1- InclisiranPart 1 - PlaceboTotal
Female729
Male224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1- InclisiranPart 1 - PlaceboTotal
Asian112
White8311
08

Study locations

11 sites
  • Excel Medical Clinical Trials LLC
    Boca Raton, Florida 33434, United States
  • Novartis Investigative Site
    Québec, Quebec G1V 4W2, Canada
  • Novartis Investigative Site
    Bron, 69677, France
  • University General Hospital of Ioannina
    Ioannina, GR 455 00, Greece
  • Metropolitan Hospital
    Athens, 18547, Greece
  • American University of Beirut Medical Center
    Beirut, 1107 2020, Lebanon
  • Hotel Dieu de France Hospital
    El Achrafiyé, 166830, Lebanon
  • Novartis Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Istanbul, TUR 34098, Turkey (Türkiye)
  • Novartis Investigative Site
    Izmir, 35100, Turkey (Türkiye)
09

References and documents

Publications

  • Wiegman A, Peterson AL, Hegele RA, Bruckert E, Schweizer A, Lesogor A, Wang Y, Defesche J. Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial. Circulation. 2025 Jun 24;151(25):1758-1766. doi: 10.1161/CIRCULATIONAHA.124.073233. Epub 2025 May 20. PubMed 40391436 ↗
  • Reijman MD, Schweizer A, Peterson ALH, Bruckert E, Stratz C, Defesche JC, Hegele RA, Wiegman A. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2022 Jul 20;29(9):1361-1368. doi: 10.1093/eurjpc/zwac025. PubMed 35175352 ↗
  • Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053. PubMed 33990512 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Oct 2023, 32 months.

Results were first posted in May 2025, 1 year 7 months after primary completion. A results delay was requested in Jun 2024.

Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 32 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2020
First posted
Dec 9, 2020
StartActual
Feb 16, 2021
Primary completionActual
Oct 30, 2023
CompletionActual
Nov 18, 2024
Results delay requested
Jun 14, 2024
Results first posted
May 31, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04659863
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
Feb 16, 2021
Primary completion
Oct 30, 2023
Completion
Nov 18, 2024
Results posted
May 31, 2025
Last update
Jan 13, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion